The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Vargatef nintedanib | Boehringer Ingelheim International GmbH | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2014-11-21 | Order → |
| Brimica Genuair aclidinium;formoterol fumarate dihydrate | Azurity Pharmaceuticals Ireland Ltd. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2014-11-19 | Order → |
| Budesonide/Formoterol Teva budesonide;formoterol | Teva Pharma B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2014-11-19 | Order → |
| Budesonide/Formoterol Teva Pharma B.V. budesonide;formoterol fumarate dihydrate | Teva Pharma B.V. | Asthma | 🇪🇺 EU 2014-11-19 | Order → |
| Duaklir Genuair aclidinium bromide;formoterol | Azurity Pharmaceuticals Ireland Ltd. | Pulmonary Disease, Chronic Obstructive | 🇪🇺 EU 2014-11-19 | Order → |
| Lymphoseek tilmanocept | Navidea Biopharmaceuticals Europe Ltd. | Radionuclide Imaging | 🇪🇺 EU 2014-11-19 | Order → |
| Rezolsta darunavir;cobicistat | HIV Infections | 🇪🇺 EU 2014-11-19 | Order → | |
| Vylaer Spiromax budesonide;formoterol | Teva Pharma B.V. | Pulmonary Disease, Chronic Obstructive; Asthma | 🇪🇺 EU 2014-11-19 | Order → |
| Ketoconazole Esteve (previously Ketoconazole HRA) ketoconazole Accelerated assessmentAdditional monitoring | Esteve Pharmaceuticals, S.A. | Cushing Syndrome | 🇪🇺 EU 2014-11-18 | Order → |
| Harvoni ledispavir;sofosbuvir Accelerated assessment | Gilead Sciences Ireland UC | Hepatitis C, Chronic | 🇪🇺 EU 2014-11-17 | Order → |
| Imbruvica ibrutinib | Janssen-Cilag International NV | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2014-10-21 | Order → |
| Busulfan Fresenius Kabi busulfan Generic | Fresenius Kabi Deutschland GmbH | Hematopoietic Stem Cell Transplantation | 🇪🇺 EU 2014-09-22 | Order → |
| Xultophy insulin degludec;liraglutide | Novo Nordisk A/S | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2014-09-18 | Order → |
| Zydelig idelalisib Additional monitoring | Gilead Sciences Ireland UC | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | 🇪🇺 EU 2014-09-18 | Order → |
| Accofil filgrastim Biosimilar | Accord Healthcare S.L.U. | 🇪🇺 EU 2014-09-17 | Order → | |
| Abasaglar (previously Abasria) insulin glargine Biosimilar | Eli Lilly Nederland B.V. | Diabetes Mellitus | 🇪🇺 EU 2014-09-09 | Order → |
| Clopidogrel/Acetylsalicylic acid Teva clopidogrel;acetylsalicylic acid | Teva Pharma B.V. | Acute Coronary Syndrome; Myocardial Infarction | 🇪🇺 EU 2014-09-01 | Order → |
| Triumeq abacavir;dolutegravir;lamivudine | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2014-08-31 | Order → |
| Velphoro sucroferric oxyhydroxide | Vifor Fresenius Medical Care Renal Pharma France | Hyperphosphatemia; Renal Dialysis | 🇪🇺 EU 2014-08-26 | Order → |
| Daklinza daclatasvir Accelerated assessment | Bristol-Myers Squibb Pharma EEIG | Hepatitis C, Chronic | 🇪🇺 EU 2014-08-22 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.